Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation

Annals of the New York Academy of Sciences

Volumn 1095, Issue , 2007, Pages 62-69

  Fimognari, Carmela ^a   Lenzi, Monia ^a   Sciuscio, Davide ^a   Cantelli Forti, Giorgio ^a   Hrelia, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Apoptosis; Caspase 3; Chemoresistance; Doxorubicin; Isothiocyanates; Murine fibroblasts; p53 Ser220 mutation; Sulforaphane

Indexed keywords

DOXORUBICIN; PROTEIN P53; SULFORAPHANE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; SERINE; SULFORAFAN; THIOCYANIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL CULTURE; CELL LINE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; FIBROBLAST; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MONOTHERAPY; MUTATION; PHENOTYPE; AMINO ACID SUBSTITUTION; ANIMAL; ARTICLE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT;

MURINAE; MUS;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; CELL LINE, TRANSFORMED; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; HUMANS; MICE; MICE, KNOCKOUT; PHENOTYPE; SERINE; THIOCYANATES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247842805     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1397.008     Document Type: Conference Paper

References (19)

1. COUKOS, G. & S.C. RUBIN. 1998. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet. Gynecol. 91: 548-552.
2. MICHALOVITZ, D., O. HALEVY & M. OREN. 1991. p53 mutations: gains or losses? J. Cell. Biochem. 45: 22-29.
3. SHAULSKY, G., N. GOLDFINGER & V. ROTTER. 1991. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res. 51: 5232-5237.
4. IWAMOTO, K.S. et al. 1996. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res. 56: 3862-3865.
5. HSIAO, M. et al. 1994. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145: 702-714.
6. LOWE, S.W. et al. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
7. KECK, A.S. & J.W. FINLEY. 2004. Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr. Cancer Ther. 3: 5-12.
8. HSU, I.C. et al. 1993. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14: 987-992.
9. MATIAS-GUIU, X. et al. 1996. p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma. Pathol. Res. Pract. 192: 1242-1249.
10. RUGGERI, B. et al. 1992. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7: 1503-1511.
11. CHO, Y. et al. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
12. GEISLER, S. et al. 2001. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61: 2505-2512.
13. CERONE, M.A. et al. 2000. p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death Differ. 7: 506-508.
14. BOSSI, G. et al. 2004. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene 23: 418-425.
15. MULLER, I. et al. 1007. Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Comm. 230: 254-257.
16. LOWN, J.W. et al. 1977. Strand scission of DNA by bound adriamycin and daunorubicin in the presence of reducing agents. Biochem. Biophys. Res. Commun. 76: 705-710.
17. ZAMAN, G.J.R. et al. 1995. Role of glutathione in the export of compounds from cells by multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA 92: 7690-7694.
18. GARIBOLDI, M.B. et al. 2003. Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int. J. Oncol. 22: 1057-1064.
19. ZHANG, Y. 2000. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 21: 1175-1182.